Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 1997

View Archived Issues

Encouraging phase I results for porcine neural cell product

Lysostaphin found superior to vancomycin in treating MRSA

SNX-111 clinical data presented at international pain meeting

U.S. patent issued for Cell Genesys CNS gene therapy

IL-2 + IFN-alpha in phase II for renal cell carcinoma

Protective effects of Bayer's LTD4 antagonist demonstrated in asthmatic subjects

Antibacterial mutilin derivatives

Cytokine inhibitors presented by SKB

Peptidoleukotrienes and TxA2 both implicated in cough variant asthma

New bradykinin antagonists from Sanofi

Antileukotriene effects described for ebastine

HIV protease inhibitors under development at Vertex

Gene therapy for AIDS in development at Theratechnologies

Pharmacia & Upjohn continues SAR studies on oxazolidinones

New treatment for ISH evaluated in humans

Single- and multiple-dose clinical studies reported for SL-91.0102

New agents for NIDDM presented by Pharmacia & Upjohn

A-5021: a potent and selective antiherpesvirus agent from Ajinomoto

Launch announced for new ulcerative colitis Rx

Third pivotal trial of VX-478 commences

RPR seeks U.K. approval for Synercid

Matrix announces restructuring to focus on oncology products

Interstim approved for marketing in U.S.

Phase I/II data on MEDI-493 presented at ICAAC

Xoma's XMP peptides display antifungal activity

Preclinical pharmacokinetic/efficacy data on MiKasome presented at ICAAC

ABT-606: a new orally active diester prodrug of H2G

Collaborators demonstrate protection against HSV with Cel-Sci vaccine

Camptosar available in Canada

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...